Efficacy of sodium-glucose cotransporter 2 inhibitor with glucagon-like peptide-1 receptor agonist for the glycemic control of a patient with Prader-Willi syndrome: a case report

Prader-Willi syndrome (PWS) is often related to severe obesity and diabetes mellitus (DM). Clinical findings suggesting the benefits of glucagon-like peptide-1 (GLP-1) receptor agonists for glycemic control of DM in PWS have been recently increasing. However, there are only a few reports describing...

Descripción completa

Detalles Bibliográficos
Autores principales: Sano, Hitomi, Kudo, Eriko, Yamazaki, Takeshi, Ito, Tomoshiro, Hatakeyama, Kinya, Kawamura, Nobuaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society for Pediatric Endocrinology 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160459/
https://www.ncbi.nlm.nih.gov/pubmed/32313377
http://dx.doi.org/10.1297/cpe.29.81

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160459/
https://www.ncbi.nlm.nih.gov/pubmed/32313377
http://dx.doi.org/10.1297/cpe.29.81

Ejemplares similares